Rosetta Genomics Announces Participation in Cantor Fitzgerald’s Inaugural “From Bench to Bedside” Healthcare Conference
July 01 2015 - 8:00AM
Business Wire
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and
provider of microRNA-based and other molecular diagnostics,
announces that company management will participate at the 2015
Inaugural “From Bench to Bedside” Healthcare Conference hosted by
Cantor Fitzgerald. The conference will take place at Le Parker
Meridien Hotel in New York City on Wednesday, July 8th. Ken Berlin,
President and Chief Executive Officer of Rosetta Genomics, will
deliver a corporate overview at 2:00 p.m. Eastern time.
Mr. Berlin’s presentation will be webcast live and can be
accessed by visiting the investor section of the company’s website
at www.rosettagenomics.com. The webcast will be archived for a
period of 90 days following the live webcast.
About Rosetta Genomics
Rosetta develops and commercializes a full range of
microRNA-based and other molecular diagnostics. Rosetta’s
integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. Through the acquisition
of PersonalizeDx, the Company offers core FISH, IHC and PCR-based
testing capabilities and partnerships in oncology and urology that
provide additional content and platforms that complement the
Rosetta offerings. Rosetta’s and PersonalizeDx’s cancer testing
services are commercially available through the Philadelphia, PA-
and Lake Forest, CA-based CAP-accredited, CLIA-certified labs,
respectively. For more information visit
www.rosettagenomics.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects constitute forward-looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including
those risks more fully discussed in the "Risk Factors" section of
Rosetta’s Annual Report on Form 20-F for the year ended December
31, 2014 as filed with the SEC. In addition, any
forward-looking statements represent Rosetta’s views only as of the
date of this release and should not be relied upon as representing
its views as of any subsequent date. Rosetta does not assume any
obligation to update any forward-looking statements unless required
by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150701005053/en/
Rosetta GenomicsKen Berlin, President & CEO(609)
419-9003investors@rosettagenomics.comorInvestor:LHAAnne
Marie Fields(212) 838-3777afields@lhai.comorBruce Voss(310)
691-7100bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Sep 2023 to Sep 2024